Zobrazeno 1 - 10
of 50
pro vyhledávání: '"SBRT, stereotactic body radiotherapy"'
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Stereotactic body radiotherapy (SBRT) is currently well-adopted as a curative treatment for primary and metastatic liver tumors. Among SBRT methods, dynamic conformal arc therapy (DCAT) and volumetric-modulated arc therapy (VMAT) are the most preferr
Externí odkaz:
https://doaj.org/article/670d1b6db8db4b48812c6149859c7e72
Autor:
Eleonora De Maio, Gabrielle Selmes, Slimane Zerdoud, Eva Jouve, R. Aziza, Jean-Louis Lacaze, Ciprian Chira, F. Izar, Florence Dalenc, C. Massabeau, Mony Ung, Anne Pradines
Publikováno v:
Breast, Vol 59, Iss, Pp 144-156 (2021)
The Breast : Official Journal of the European Society of Mastology
The Breast : Official Journal of the European Society of Mastology
Does oligometastatic breast cancer (OMBC) deserve a dedicated treatment? Although some authors recommend multidisciplinary management of OMBC with a curative intent, there is no evidence proving this strategy beneficial in the absence of a randomized
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol 19, iss 8
Clinical Gastroenterology and Hepatology
Clinical Gastroenterology and Hepatology
The Coronavirus disease 2019 (COVID-19) pandemic is expected to have a long-lasting impact on the approach to care for patients at risk for and with hepatocellular carcinoma (HCC) due to the risks from potential exposure and resource reallocation. Th
Autor:
Alex K. Bryant, Nikhil V. Kotha, Daniel R Cherry, Brent S. Rose, Vinit Nalawade, Tyler F. Stewart
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 28, Iss, Pp 133-140 (2021)
Clinical and Translational Radiation Oncology
Clinical and Translational Radiation Oncology
Highlights • Neutrophil-lymphocyte ratio is a promising prognostic marker for several cancers. • NLR is not useful as a marker of lung cancer survival in localized lung cancer. • NLR has potential as a marker of competing mortality risk in loca
Publikováno v:
EBioMedicine, Vol 59, Iss, Pp 102975-(2020)
EBioMedicine
Elsevier
EBioMedicine
Elsevier
© 2020 The Author(s) Natural Killer (NK) cells and CD8+ cytotoxic T cells are two types of immune cells that can kill target cells through similar cytotoxic mechanisms. With the remarkable success of chimeric antigen receptor (CAR)-engineered T (CAR
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 10 (2020)
Frontiers in Oncology, Vol 10 (2020)
Stereotactic body radiotherapy (SBRT) is currently well-adopted as a curative treatment for primary and metastatic liver tumors. Among SBRT methods, dynamic conformal arc therapy (DCAT) and volumetric-modulated arc therapy (VMAT) are the most preferr
Autor:
Madeleine Lichtenecker, Maria-Therese Kasseroler, Daniel Dejaco, Andrea Posch, Maria Anegg, Britta C. Forthuber, Herbert Riechelmann, Teresa Bernadette Steinbichler, Volker Hans Schartinger, Barbara Kofler
Publikováno v:
Cancers
Cancers, Vol 10, Iss 11, p 421 (2018)
Volume 10
Issue 11
Cancers, Vol 10, Iss 11, p 421 (2018)
Volume 10
Issue 11
Background: Following first-line treatment of head and neck cancer (HNC), persistent disease may require second-line treatment. Methods: All patients with HNC treated between 2008 and 2016 were included. Second-line treatment modalities and survival
Autor:
Jennifer F. Tseng, Rabia N Dagoglu, Mark P. Callery, Rebecca A. Miksad, Anand Mahadevan, Tara S. Kent, James Moser, Andrea J. Bullock, Joseph D. Mancias
Publikováno v:
Journal of Cancer
451 Background: After adjuvant or definitive radiation for pancreas cancer, there are limited conventional treatment options for recurrent pancreas cancer. We explored the role of (Stereotactic Body Radiotherapy) SBRT for reirradiation of recurrent p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
H. Cem Onal, Berna Akkus Yildirim, Nese Torun, Erkan Topkan, Aylin Güneşli Yetişken, Ali Ayberk Besen, Yurday Ozdemir, Ozan Cem Guler
Publikováno v:
Journal of Bone Oncology
Journal of Bone Oncology, Vol 15, Iss, Pp-(2019)
Journal of Bone Oncology, Vol 15, Iss, Pp-(2019)
Highlights • SBRT provides a satisfying local control rate of 88% in patients with spMets. • Post-SBRT vertebral compression rate of 4% corresponds to the current literature. • >6 months of bisphosphonates use is associated with lower fracture-